Brian Carey
Partner Global Regulatory
-
Overview
-
Experience
-
Credentials
-
Insights and events
For over two decades, Brian Carey has advised life sciences and health care companies on complex regulatory and legislative health policy matters. He has extensive experience advising biopharma clients on complex Medicare coverage, payment, and compliance matters. Brian’s experience advocating before the U.S. Department of Health and Human Services, Centers for Medicare & Medicaid Services, and U.S. Congress provides his clients with the confidence and insights to recognize regulatory risk and opportunities to promote adoption of new technologies.
Brian regularly advises innovative medical technology developers, medical trade associations, leading clinical laboratories, and molecular diagnostic companies through the evolving regulatory requirements to commercialize new technologies successfully. His practice focuses on addressing regulatory challenges for Laboratory Developed Tests, assessing payment under the Protecting Access to Medicare Act of 2014 (PAMA), and establishing coverage pathways with public and private payers.
Representative experience
Enabled a pharmaceutical to obtain the first Medicare New Technology Add on Payment (NTAP) for an oral therapy.*
Helped CMS design and create one of the first data registries in its CED program, by advising a coalition of leading academic medical centers and medical device manufacturers.*
Advised leading molecular diagnostic company on the development of the current Medicare coverage, payment, and coding challenges on the Clinical Laboratory Fee Schedule (CLFS).*
Developed novel legal arguments and assembled compelling scientific evidence that successfully reversed an adverse policy decision affecting the coding and payment for biotechnology product.*
Presented legal arguments for a new medical technology that led to the creation of a new DRG for an inpatient hospital payment.*
Represented a biotechnology client before CMS and Congress, leading to the creation of a new payment methodology for therapeutic radiopharmaceuticals based on the Average Sales Price methodology.*
Advised numerous clinical laboratories on the local coverage process with Medicare Administrative Contractors.*
*Matter handled prior to joining Hogan Lovells.
Credentials
- J.D., Boston College Law School, magna cum laude, 1997
- B.S.E., Wharton School of Business, Philadelphia, 1992
- B.A., University of Pennsylvania, 1992
- Massachusetts
- New York
- District of Columbia
- U.S. Court of Appeals, First Circuit
- U.S. District Court, Southern District of New York
- U.S. District Court, District of Massachusetts